Drug Profile


Alternative Names: DWP-401; Easyef; Recombinant human epidermal growth factor - Daewoong; rhEGF - Daewoong

Latest Information Update: 07 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Growth factors; Skin disorder therapies
  • Mechanism of Action Epidermal growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diabetic foot ulcer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Alopecia; Diabetic foot ulcer; Wounds
  • Phase III Stomatitis

Most Recent Events

  • 05 Jun 2015 Phase-III development for Stomatitis is ongoing in South Korea
  • 03 Sep 2014 Launched for Diabetic foot ulcer in Vietnam, Philippines and Thailand (Topical) prior to September 2014
  • 03 Sep 2014 Launched for Wounds in Vietnam, Philippines and Thailand (Topical) prior to September 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top